BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33723371)

  • 1. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials.
    Desai A; Gainor JF; Hegde A; Schram AM; Curigliano G; Pal S; Liu SV; Halmos B; Groisberg R; Grande E; Dragovich T; Matrana M; Agarwal N; Chawla S; Kato S; Morgan G; Kasi PM; Solomon B; Loong HH; Park H; Choueiri TK; Subbiah IM; Pemmaraju N; Subbiah V;
    Nat Rev Clin Oncol; 2021 May; 18(5):313-319. PubMed ID: 33723371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 vaccines for cancer patients: a call to action.
    Corti C; Crimini E; Tarantino P; Pravettoni G; Eggermont AMM; Delaloge S; Curigliano G
    Eur J Cancer; 2021 May; 148():316-327. PubMed ID: 33770576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.
    Hwang JK; Zhang T; Wang AZ; Li Z
    J Hematol Oncol; 2021 Feb; 14(1):38. PubMed ID: 33640005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET).
    Body A; Ahern E; Lal L; Gillett K; Abdulla H; Opat S; O'Brien T; Downie P; Turville S; Munier CML; Smith C; MacIntyre CR; Segelov E
    BMC Infect Dis; 2022 Jan; 22(1):70. PubMed ID: 35057745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients.
    Gundavda MK; Gundavda KK
    Curr Treat Options Oncol; 2021 Sep; 22(10):95. PubMed ID: 34515857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 vaccine trials: The potential for "hybrid" analyses.
    Fleming TR; Nason M; Krause PR; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Aug; 18(4):391-397. PubMed ID: 34041932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Vaccination: Guidance for Ethical, Informed Consent in a National Context.
    Little DT; Šeman EI; Walsh AL
    Issues Law Med; 2021; 36(2):127-162. PubMed ID: 36629774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
    Fleming TR; Krause PR; Nason M; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Jun; 18(3):335-342. PubMed ID: 33535811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges.
    Cooper DM; Afghani B; Byington CL; Cunningham CK; Golub S; Lu KD; Radom-Aizik S; Ross LF; Singh J; Smoyer WE; Lucas CT; Tunney J; Zaldivar F; Ulloa ER
    Pediatr Res; 2021 Nov; 90(5):966-970. PubMed ID: 33627824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.
    Fendler A; de Vries EGE; GeurtsvanKessel CH; Haanen JB; Wörmann B; Turajlic S; von Lilienfeld-Toal M
    Nat Rev Clin Oncol; 2022 Jun; 19(6):385-401. PubMed ID: 35277694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. India begins COVID-19 vaccination amid trial allegations.
    Bhuyan A
    Lancet; 2021 Jan; 397(10271):264. PubMed ID: 33485435
    [No Abstract]   [Full Text] [Related]  

  • 17. COVID-19 immunization in people with cancer-Is it safe and efficient? What do we know?
    Lazăr DE; Munteanu A
    Tumori; 2022 Oct; 108(5):420-430. PubMed ID: 35426773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
    Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
    Elife; 2023 Mar; 12():. PubMed ID: 36975207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
    Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
    Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
    Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.